| Title | 123I-Ioflupane spect scintigraphy in patients with movement disorders | |
| Authors | A. Zissimopoulos, N. Boussios, D. Fistouris, V. Pardalis and E. Karathanos
Nuclear Medicine Department, Democritus University of Thrace, Alexandroupolis, Hellas |
|
| Citation | Zissimopoulos, A., Boussios, N., Fistouris, D., Pardalis, V., Karathanos, E.: 123I-Ioflupane spect scintigraphy in patients with movement disorders, Epitheorese Klin. Farmakol. Farmakokinet. 24(1): 31-34 (2010) | |
| Publication Date | Accepted for publication (Final Version): April 10, 2010 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Parkinson’s disease, Parkinsonian syndromes, cintigraphic imaging, 123I-Ioflupane. | |
| Other Terms | review article | |
| Summary | Parkinson’s disease (PD) may present heterogeneously and also be confused with parkinsonism caused by other disorders like multiple system atrophy, or essential tremor. Neuroimaging studies, are important for the detection of PD, especially in the early stages of the disease. Dopamine transporter (DAT) imaging with 123I-Ioflupane has been developed to directly measure degeneration of dopamine presynaptic terminal. The aim of this study is the differentiation of patients with clinically uncertain Parkinsonian Syndromes, from essential tremor (ET) and idiopathic Parkinson’s disease with scintigraphic imaging with 123IIoflupane. Sixteen consecutive patients with movement disorders, during a period of two years, were included in the study. All patients underwent 123I-FP-CIT SPECT. Findings were normal in 11 patients. The remainder 5 showed an asymmetrical reduction in DaT uptake, more pronounced in the putamen, consistent with the pattern seen in PD. 123I-FP-CIT SPECT imaging correctly identified the 5 patients with clinically certain PD. In the remainder 11 patients, with the classic criteria of ET and mixed types of tremor, the normal imaging pattern ruled out the diagnosis of PD. This study shows that DAT imaging is a sensitive marker for identifying subjects with Parkinson’s disease and differentiating them from essential tremor. | |
| References | 1. Hughes A.J., Daniel S.E., Blankson S., Lees A.J.: A clinicopathological study of 100 cases of Parkinson’s disease. Arch. Neurol. 50: 140-148 (1993)
2. Hughes A.J., Daniel S.E., Ben Shlomo Y., Lees A.J.: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125: 861-870 (2002) 3. Tatsch K.: Imaging of the dopaminergic system in parkinsonism with SPET. Nucl. Med. Commun. 22: 819-827 (2001) 4. Deuschl G., Bain M., Brin M.: Consensus statement of the movement disorder society on tremor. Ad hoc scientific committee. Mov. Disord. 13: 2-23 (1988) 5. Benamer T.S.: Accurate differentiation of parkinsonism essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov. Disord. 15: 503-510 (2000) 6. Hughes A.J., Daniel S.E., Kilford L., Lees A.J.: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55: 181-184 (1992) 7. Gelb D.J., Oliver E., Gilman S.: Diagnostic criteria for Parkinson disease. Arch. Neurol. 56: 33-39 (1999) 8. Brooks DJ.: Imaging end points for monitoring neuroprotection in Parkinson’s disease. Ann. Neurol. 53(Suppl. 3): S110-S118 (2003) 9. Parkinson Study Group: A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 55: 1540-1547 (2000) 10. Booij J., Tissingh G., Winogrodzka A., van Royen E.A.: Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur. J. Nucl. Med. 26: 171-182 (1999) 11. Pirker W., Asenbaum S., Bencsits G., et al.: [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov. Disord. 15: 1158-1167 (2000) 12. Rajput A.H., Rozdilsky B., Ang L., Rajput A.: Significance of parkinsonian manifestations in essential tremor. Can. J. Neurol. Sci. 20: 114-117 (1993) 13. Cohen O., Pullman S., Jurewicz E., Watner D., Louis E.D.: Rest tremor in patients with essential tremor. Arch. Neurol. 60: 405-410 (2003) 14. Roy M., Boyer L., Barbeau A.: A prospective study of 50 cases of familial Parkinson’s disease. Can. J. Neurol. Sci. 10: 37-42 (1983) 15. Geraghty J.J., Jankovic J., Zetusky W.J.: Association between essential tremor and Parkinson’s disease. Ann. Neurol. 17: 329-333 (1985) 16. Marshall V., Grosset D.G.: (2003) Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov. Disord. 18(Suppl. 7): S22-S27 (2003) 17. Lee M.S., Kim Y.D., Im J.H., Kim H.J., Rinne J.O., Bhatia K.P.: 123I-IPT brain SPECT study in essential tremor and Parkinson’s disease. Neurology 52: 1422-1426 (1999) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2010 – ANNUAL SUBSCRIPTION 2010 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|